Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer
The aim of this study is to confirm the Efficacy,the Safety and the Quality of Life after TOOKAD® Soluble VTP in localized prostate cancer patients.
Prostate Cancer
DRUG: TOOKAD® Soluble
To confirm that a significant proportion of patients will be prostate cancer free on the biopsy., Number of patients with a negative biopsy., Month 12
Changes in urinary and erectile functions and their potential impact on quality of life using International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF) and the General quality of life (EQ5D) questionnaires., Patients' reported outcome measures (PROMs) impairment: urinary symptoms using IPSS and erectile functions using IIEF. Quality of life using EQ5D will also be described, Screening, 1, 3, 6 and 12 months after completing treatment|The rate of adverse events., Adverse event reporting., Screening-Month 12|The overall cancer burden in the prostate determined by biopsy as compared to baseline., Total length of cancer present in all cores taken in any given biopsy session, Month 12|The rate of severe prostate cancer related events: cancer extension to T3, metastasis and prostate cancer related death, Severe prostate cancer related events: cancer extension to T3, metastasis or prostate cancer-related death., Screening-Month 12
The study is designed as a multicenter, single-arm, open label, 12 months follow-up clinical trial. Men with localized prostate cancer will be treated with TOOKAD® Soluble VTP under general anesthesia.

Patients will be followed-up for 12 months with patient questionnaires on QoL, erectile and urinary functions, clinical evaluation with study visits at 1, 3, 6 and 12 months , Prostate Specific Antigen(PSA) testing at 3, 6 and 12 months. In addition, they will have biopsy at 6 months (± 2) and 12 months.